Brief: TScan Therapeutics Q4 Net Income USD -19.613 Million
06/03/2024 12:00
Mar 06 (Reuters) - TScan Therapeutics Q4 collaboration and license revenue USD 7.211 million. * Q4 basic EPS USD -0.21 * Q4 income from operations USD -21.357 million * Q4 operating expenses USD 28.568 million
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing